Benzinga | Mar 9, 2021 05:16AM EST

Rigel Pharmaceuticals Awarded U.S. Patent 10,941,140 'IRAK inhibitors and method for making and using'

Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.